Citryll
PrivateLast Round
Series B
Dec 9, 2024
Total Funding Raised
$110.96M
Company Overview
Citryll is a biotechnology company that develops pharmaceutical drugs designed to treat autoimmune and other human diseases by targeting Neutrophil Extracellular Traps (NETs).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Citryll Comparables
Compare Citryll with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neutrolis Inc | 85% | |
| Bristol Myers Squibb | 72% | |
| AstraZeneca | 69% | |
Citryll Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 9, 2024 | ||||
| Grant | Oct 3, 2024 | ||||
| Series A | Jul 2, 2020 | ||||
| Grant | Jul 2, 2020 |
Key People
Founding team and executive leadership
Citryll Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series B |
| Brabantse Ontwikkelings Maatschappij | Series B |
| BOM Brabant Ventures | Series B, Series A |
| Pureos Bioventures | Series B |
| BioGeneration Ventures | Series B, Series A |
| Bgvcat | Series A, Series B |
| Johnson & Johnson Innovation - JJDC, Inc. | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 15, 2026
Developing the first ET-targeting therapy for immune-mediated inflammatory diseases.
- Jun 30, 2025
CIT-013 is a first-in-class antibody for immune-mediated inflammatory diseases.
Citryll Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Citryll's valuation, stock price, and market status.